Virbac Logo

Virbac

Develops animal health pharma, vaccines & diagnostics for vets, farmers & pet owners globally.

FR000 | PA

Overview

Corporate Details

ISIN(s):
FR0000031577
LEI:
969500QQ1X5XHG649644
Country:
France
Address:
1ERE AVENUE, 06510 CARROS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Virbac is an independent pharmaceutical company exclusively dedicated to animal health. Founded in 1968 by a veterinarian, the company develops, manufactures, and distributes a comprehensive range of products and services for veterinarians, farmers, and pet owners. Operating in over 100 countries, its portfolio offers innovative solutions covering the majority of animal species and diseases. Key product areas include pharmaceuticals, vaccines, parasite control, dental care, nutritional supplements, and diagnostic tools, all aimed at shaping the future of animal health.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-16 17:45
Earnings Release
VIRBAC annonce son chiffre d'affaires pour le troisième trimestre 2025
French 585.4 KB
2025-10-16 17:45
Earnings Release
VIRBAC Announces Third Quarter 2025 Sales
English 627.5 KB
2025-09-12 17:45
Earnings Release
VIRBAC: résultats semestriels 2025
French 1.2 MB
2025-09-12 17:45
Earnings Release
Virbac: 2025 Half-year results
English 1.1 MB
2025-09-12 17:30
Interim Report
Virbac : Rapport financier semestriel 2025
French 13.2 MB
2025-09-12 17:30
Interim Report
Virbac : Half-yearly financial report 2025
English 13.4 MB
2025-09-12 17:30
Report Publication Announcement
Virbac : Communiqué de mise à disposition du rapport financier semestriel au 30…
French 264.9 KB
2025-09-12 17:30
Report Publication Announcement
Virbac : Public release of the Half-Year Financial Report at 30 June 2025.
English 264.6 KB
2025-08-18 09:30
Remuneration Information
VIRBAC: Informations sur les conditions de rémunération de Paul Martingell
French 80.5 KB
2025-08-18 09:30
Remuneration Information
Virbac:: Paul Martingell's compensation terms
English 128.7 KB
2025-06-19 08:30
Board/Management Information
VIRBAC: Paul Martingell nommé directeur général du groupe Virbac au 1er septemb…
French 271.7 KB
2025-06-19 08:30
Board/Management Information
VIRBAC: Paul Martingell is appointed chief executive officer of Virbac, effecti…
English 279.3 KB
2025-06-10 09:59
Declaration of Voting Results & Voting Rights Announcements
Virbac : Declaration of the number of share and voting rights 05/2025
English 59.2 KB
2025-06-10 09:59
Declaration of Voting Results & Voting Rights Announcements
Virbac : Déclaration d'actions et de droits de vote 05/2025
French 36.6 KB
2025-05-26 10:05
Pre-Annual General Meeting Information
VIRBAC: Communiqué précisant les modalités de mise à disposition ou de consulta…
French 26.3 KB

Automate Your Workflow. Get a real-time feed of all Virbac filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Virbac

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Virbac via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-04-17 N/A Other Sell 370 135,790.00 EUR
2023-07-19 N/A Other Buy 950 245,100.00 EUR

Peer Companies

OS Therapies Inc Logo
Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.
United States of America
OSTX
Otsuka Holdings Co., Ltd. Logo
Global healthcare group creating pharmaceuticals and nutraceuticals for worldwide well-being.
Japan
4578
Outlook Therapeutics, Inc. Logo
Developing an ophthalmic bevacizumab to treat retinal diseases like wet AMD.
United States of America
OTLK
Ovid Therapeutics Inc. Logo
Developing targeted small molecule therapies for rare neurological diseases and epilepsies.
United States of America
OVID
Ovoca Bio Plc Logo
Biopharma developing a novel therapy for premenopausal women with low sexual desire (HSDD).
Ireland
OVXA
Oxford Biomedica PLC Logo
A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.
United Kingdom
OXB
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo
A former biopharma firm that developed non-addictive, cannabinoid-based pain therapies.
United Kingdom
OCTHF
Pacira BioSciences, Inc. Logo
Advancing non-opioid therapies for postsurgical, chronic, and musculoskeletal pain.
United States of America
PCRX
PAINREFORM LTD. Logo
Specialty pharma developing extended-release drugs for post-operative pain management.
United States of America
PRFX
PAION AG Logo
Developed drugs for hospital-based sedation, anesthesia, and critical care.
Germany
PA8

Talk to a Data Expert

Have a question? We'll get back to you promptly.